InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update
VANCOUVER, British Columbia, Sept. 23, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022.
Related news for (INM)
- InMode to Report Third Quarter 2025 Financial Results and Hold Conference Call on November 5, Expects Q3 Revenue Between $92.5M-$93.0M, Reiterates FY 2025 Guidance Between $365M-$375M
- InMode to Present at Baird 2025 Global Healthcare Conference
- InMode to Participate in Upcoming Investor Conferences
- Don’t Miss Out: MoBot’s Latest Stock Updates 08/04/25 08:00 AM
- INmune Bio’s INKmune CaRe PC Trial in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints
